A5037889393- Neurotransmitter Receptor Influence on Behavior
- Neuroscience and Neuropharmacology Research
- Receptor Mechanisms and Signaling
- Treatment of Major Depression
- Mental Health Research Topics
- Epilepsy research and treatment
- Design Education and Practice
- Pharmacological Effects and Assays
- Functional Brain Connectivity Studies
- Neuroscience and Neural Engineering
- Pharmacological Receptor Mechanisms and Effects
- Circadian rhythm and melatonin
- Sleep and Wakefulness Research
- Sleep and related disorders
- Neural dynamics and brain function
- Chemical synthesis and alkaloids
Royal Ottawa Mental Health Centre
2024
University of Ottawa
2024
McGill University
1991-2000
Université de Montréal
1984
1. The aim of the present study was to investigate putative modulation locus coeruleus (LC) noradrenergic (NA) neurones by 5-hydroxytryptaminergic (5-HT) system use in vivo extracellular unitary recordings and microiontophoresis anaesthetized rats. To this end, potent selective 5-HT1A receptor antagonist WAY 100635 (N-[2-[4(2-methoxyphenyl)-1-piperazinyl]-N-(2-pyridinyl) cyclohexanecarboxamide trihydroxychloride) used. 2. In dorsal hippocampus, both local (by microiontophoresis, 20 nA)...
Regulation of the electrically evoked release [3H]5-HT was examined in midbrain, frontal cortex and hippocampus preloaded slices obtained from wild-type 5-HT1B knock-out mice. In absence any drug released increased midbrain but not [3H]5-HT1B knock out The selective agonist CP 93129 5-HT1B/1D sumatriptan, inhibited cortical control mice had no effect mutants. two projection areas studied, non-selective 5-HT 5-carboxyamidotryptamine (5-CT) both groups mice, indicating that additional...
Duloxetine is a dual serotonin (5-HT)/norepinephrine (NE) re-uptake blocker with antidepressant potential. In the present in vivo electrophysiological study, changes function of rat 5-HT and NE systems after 2- 21-day administration duloxetine (20 mg/kg/day) were assessed dorsal hippocampus raphe nucleus (DRN). The firing rate DRN neurons was decreased 2 days duloxetine, but returned to control level administration. This recovery presumably due desensitization somatodendritic 5-HT1A...
Addition of dopamine (DA)/serotonin (5-HT) partial agonists to 5-HT/norepinephrine (NE) reuptake inhibitors are commonly used enhance the antidepressant response. The simultaneous inhibition 5-HT and NE transporters with venlafaxine its combination brexpiprazole, which blocks α
Current pharmacological agents for depression have limited efficacy in achieving remission. Developing and validating new medications is challenging due to biological targets. This study aimed link electrophysiological data symptom improvement better understand mechanisms underlying treatment response. Longitudinal changes neural oscillations were assessed using resting-state electroencephalography (EEG) from two Canadian Biomarker Integration Network Depression studies, involving cognitive...
Abstract Aim Individuals with insomnia frequently have comorbid depression or anxiety. This study sought to provide a preliminary indication of the effects lemborexant (LEM) in subjects treated for mild depression/anxiety symptoms. Methods E2006‐G000‐303 (NCT02952820; EudraCT 2015‐001463‐39; SUNRISE‐2) was 12‐month, phase 3, randomized, placebo‐controlled, double‐blind where disorder were randomized (1:1:1) placebo, LEM 5 mg (LEM5), 10 (LEM10) 6 months. During second months (not reported),...